Cargando…

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer

Conventional cytotoxic chemotherapy involving DNA-interacting agents and indiscriminate cell death is no longer the future of cancer management. While chemotherapy is not likely to completely disappear from the armamentarium; the use of targeted therapies in combination with conventional treatment i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dervisis, Nikolaos, Klahn, Shawna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644617/ https://www.ncbi.nlm.nih.gov/pubmed/29056714 http://dx.doi.org/10.3390/vetsci3010004

Ejemplares similares

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study
por: Klahn, Shawna, et al.
Publicado: (2022)

Hemophagocytic syndrome in a cat
por: Wilkinson, Ashley R, et al.
Publicado: (2018)

Clinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemotherapy
por: Latifi, Max, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Histotripsy ablation for the treatment of feline injection site sarcomas: a first-in-cat in vivo feasibility study
por: Ruger, Lauren, et al.
Publicado: (2023)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

High intensity focused ultrasound for the treatment of solid tumors: a pilot study in canine cancer patients
por: Carroll, Jennifer, et al.
Publicado: (2022)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer
por: Jerin, Samanta, et al.
Publicado: (2023)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
por: Kleczko, Emily K., et al.
Publicado: (2018)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
por: Assi, Ahmad, et al.
Publicado: (2023)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tbpn66ene7iqhu2ao7m4fu5sth